Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alliance Pharma Plc's subsidiary acquires Lypsyl brand from Novartis AG


Wednesday, 18 Dec 2013 02:00am EST 

Alliance Pharma Plc:Says its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired all UK and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG ( Novartis) for a consideration of $3.0 million.Says Lypsyl is a personal care brand used to moisturise lips.Says Novartis and its affiliates (the Novartis Group) have been selling Lypsyl in the UK and ROI for many years.Says the $3.0 million consideration is being funded from available cash and the group's 25 million pounds acquisition facility remains undrawn. 

Company Quote

84.15
-0.5 -0.59%
6:54am EDT